Advertisement

Topics

CureDuchenne Ventures Invests in New Gene Editing Company Exonics Therapeutics to Advance CRISPR/Cas9 Therapy for Duchenne Muscular Dystrophy

07:35 EST 27 Feb 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
CureDuchenne Ventures, a subsidiary of the nonprofit CureDuchenne that funds research to find a cure for Duchenne muscular dystrophy, announced today that they have committed $5 million in seed financing in Exonics Therap...

Other Sources for this Article

CureDuchenne
Karen Harley, 949-872-2552

NEXT ARTICLE

More From BioPortfolio on "CureDuchenne Ventures Invests in New Gene Editing Company Exonics Therapeutics to Advance CRISPR/Cas9 Therapy for Duchenne Muscular Dystrophy"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Muscular Dystrophy
Muscular dystrophy is a group of degenerative inherited disorders causing muscle weakness and loss of muscle tissue. The different types are Becker muscular dystrophy, Duchenne muscular dystrophy, Emery-Dreifuss muscular dystrophy, Facioscapulohumeral mu...

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...